The common sense model applied to hepatitis C: A qualitative analysis of the impact of disease comparison and witnessed death on hepatitis C illness perception

Harm Reduction Journal

Volumn 12, Issue 1, 2015, Pages

  Safo, Stella A ^a   Batchelder, Abigail ^a,b   Peyser, Deena ^a,c   Litwin, Alain H ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c RUTGERS UNIVERSITY   (United States)

Author keywords

Hepatitis C (HCV); HIV AIDS; Illness perception; People who inject drugs (PWID); Substance use; Treatment barriers

Indexed keywords

PEGINTERFERON ALPHA2A; RIBAVIRIN; TELAPREVIR;

ADULT; ARTICLE; ATTITUDE TO ILLNESS; DEATH; DECISION MAKING; DISEASE SEVERITY; DRUG EFFICACY; FATALITY; HEALTH IMPACT ASSESSMENT; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; MIXED INFECTION; PATIENT ATTITUDE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SEMI STRUCTURED INTERVIEW; SOCIAL INTERACTION; SUBSTANCE ABUSE; UNITED STATES; URBAN AREA; ATTITUDE TO DEATH; ATTITUDE TO HEALTH; COMPLICATION; EVALUATION STUDY; FEMALE; HEALTH CARE DELIVERY; HEALTH SERVICE; INTERVIEW; MALE; MIDDLE AGED; NEW YORK; PSYCHOLOGY;

ATTITUDE TO DEATH; FEMALE; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HEALTH SERVICES ACCESSIBILITY; HEALTH SERVICES NEEDS AND DEMAND; HEPATITIS C; HUMANS; INTERVIEWS AS TOPIC; MALE; MIDDLE AGED; NEW YORK CITY; SUBSTANCE ABUSE, INTRAVENOUS;

EID: 84932601361     PISSN: None     EISSN: 14777517     Source Type: Journal    
DOI: 10.1186/s12954-015-0054-1     Document Type: Article

References (43)

1. Ward JW. The hidden epidemic of hepatitis C virus infection in the United States: occult transmission and burden of disease. Top Antivir Med. 2013;21(1):15-9.
2. Kohli A, Shaffer A, Sherman A, Kottilil S. Treatment of hepatitis C: a systematic review. JAMA. 2014;312(6):631-40.
3. Naggie S. Management of hepatitis C virus infection: the basics. Top Antivir Med. 2012;20(5):154-61.
4. Sublette VA, Smith SK, George J, McCaffery K, Douglas MW. The hepatitis C treatment experience: patients' perceptions of the facilitators of and barriers to uptake, adherence and completion. Psychol Health. 2015;30(8):1-18.
5. Yehia BR, Schranz AJ, Umscheid CA, Re III VL. The treatment cascade for chronic hepatitis C virus infection in the United States: a systematic review and meta-analysis. PLoS One. 2014;9(7):e101554.
6. Zeremski M, Zibbell JE, Martinez AD, Kritz S, Smith BD, Talal AH. Hepatitis C virus control among persons who inject drugs requires overcoming barriers to care. World J Gastroenterol. 2013;19(44):7846.
7. Grebely J, Dore GJ. Can hepatitis C virus infection be eradicated in people who inject drugs? Antiviral Res. 2014;104:62-72.
8. Bruggmann P, Grebely J. Prevention, treatment and care of hepatitis C virus infection among people who inject drugs. International Journal of Drug Policy. 2014. doi: 10.1016/j.drugpo.2014.08.014 .
9. Zickmund SL, Campbell SA, Tirado CF, Zook CL, Weinrieb RM. Perceived barriers to hepatitis C therapy for patients receiving opioid agonist treatment. J Addict Med. 2012;6(3):233-9.
10. Mravčík V, Strada L, Štolfa J, Bencko V, Groshkova T, Reimer J, et al. Factors associated with uptake, adherence, and efficacy of hepatitis C treatment in people who inject drugs: a literature review. Patient preference and adherence. 2013;7:1067.
11. Swan D, Long J, Carr O, Flanagan J, Irish H, Keating S, et al. Barriers to and facilitators of hepatitis C testing, management, and treatment among current and former injecting drug users: a qualitative exploration. AIDS Patient Care STDS. 2010;24(12):753-62.
12. Barocas JA, Brennan MB, Hull SJ, Stokes S, Fangman JJ, Westergaard RP. Barriers and facilitators of hepatitis C screening among people who inject drugs: a multi-city, mixed-methods study. Harm Reduct J. 2014;11:1.
13. Treloar C, Rhodes T. The lived experience of hepatitis C and its treatment among injecting drug users: qualitative synthesis. Qual Health Res. 2009;19(9):1321-34.
14. McNeil R, Small W. 'Safer environment interventions': a qualitative synthesis of the experiences and perceptions of people who inject drugs. Soc Sci Med. 2014;106:151-8.
15. Arain A, Robaeys G. Eligibility of persons who inject drugs for treatment of hepatitis C virus infection. World J Gastroenterol. 2014;20(36):12722-33.
16. Harris M, Rhodes T. Hepatitis C treatment access and uptake for people who inject drugs: a review mapping the role of social factors. Harm Reduct J. 2013;10(1):7.
17. Jordan AE, Masson CL, Mateu-Gelabert P, McKnight C, Pepper N, Bouche K, et al. Perceptions of drug users regarding Hepatitis C screening and care: a qualitative study. Harm Reduction Journal. 2013;10:10.
18. Rosen HR. Chronic hepatitis C infection. N Engl J Med. 2011;364(25):2429-38.
19. Miller ER, McNally S, Wallace J, Schlichthorst M. The ongoing impacts of hepatitis C-a systematic narrative review of the literature. BMC Public Health. 2012;12:672.
20. Jones L, Atkinson A, Bates G, McCoy E, Porcellato L, Beynon C, et al. Views and experiences of hepatitis C testing and diagnosis among people who inject drugs: systematic review of qualitative research. Int J Drug Pol. 2014;25(2):204-11.
21. Bruggmann P, Litwin AH. Models of care for the management of hepatitis C virus among people who inject drugs: one size does not fit all. Clin Infect Dis. 2013;57 Suppl 2:S56-61.
22. Strauss SM, Munoz-Plaza C, Tiburcio NJ, Astone-Twerell J, Des Jarlais DC, Gwadz M, et al. Barriers and facilitators to undergoing hepatitis C virus (HCV) testing through drug treatment programs. J Drug Iss. 2008;38(4):1161-85.
23. Davis M, Rhodes T, Martin A. Preventing hepatitis C: 'common sense', 'the bug' and other perspectives from the risk narratives of people who inject drugs. Soc Sci Med. 2004;59(9):1807-18.
24. Rhodes T, Treloar C. The social production of hepatitis C risk among injecting drug users: a qualitative synthesis. Addiction. 2008;103(10):1593-603.
25. Rasi M, Künzler-Heule P, Schmid P, Semela D, Bruggmann P, Fehr J, et al. " Fighting an uphill battle": experience with the HCV triple therapy: a qualitative thematic analysis. BMC Infect Dis. 2014;14:507.
26. Conrad S, Garrett LE, Cooksley WG, Dunne MP, MacDonald GA. Living with chronic hepatitis C means 'you just haven't got a normal life any more'. Chronic Illn. 2006;2(2):121-31.
27. Hale ED, Treharne GJ, Kitas GD. The common-sense model of self-regulation of health and illness: how can we use it to understand and respond to our patients' needs? Rheumatology (Oxford). 2007;46(6):904-6.
28. Leventhal H, Leventhal EA, Breland JY. Cognitive science speaks to the "common-sense" of chronic illness management. Ann Behav Med. 2011;41(2):152-63.
29. Diefenbach MA, Leventhal H. The common-sense model of illness representation: theoretical and practical considerations. Journal of social distress and the homeless. 1996;5(1):11-38.
30. McAndrew LM, Musumeci-Szabó TJ, Mora PA, Vileikyte L, Burns E, Halm EA, et al. Using the common sense model to design interventions for the prevention and management of chronic illness threats: from description to process. Br J Health Psychol. 2008;13(2):195-204.
31. Leventhal H, Meyer D, Nerenz D. The common sense representation of illness danger. Contributions to medical psychology. 1980;2:7-30.
32. Meyer D, Leventhal H, Gutmann M. Common-sense models of illness: the example of hypertension. Health Psychol. 1985;4(2):115.
33. Sutton R, Treloar C. Chronic illness experiences, clinical markers and living with hepatitis C. J Health Psychol. 2007;12(2):330-40.
34. Lang CA, Conrad S, Garrett L, Battistutta D, Cooksley WGE, Dunne MP, et al. Symptom prevalence and clustering of symptoms in people living with chronic hepatitis C infection. J Pain Symptom Manage. 2006;31(4):335-44.
35. Krauskopf K, McGinn T, Federman A, Halm E, Leventhal H, McGinn L, et al. HIV and HCV health beliefs in an innercity community. J Viral Hepat. 2011;18(11):785-91.
36. Munoz-Plaza CE, Strauss S, Astone-Twerell J, Des Jarlais D, Gwadz M, Hagan H, et al. Exploring drug users' attitudes and decisions regarding hepatitis C (HCV) treatment in the US. Int J Drug Pol. 2008;19(1):71-8.
37. Litwin AH, Berg KM, Li X, Hidalgo J, Arnsten JH. Rationale and design of a randomized controlled trial of directly observed hepatitis C treatment delivered in methadone clinics. BMC Infect Dis. 2011;11:315.
38. Roose RJ, Cockerham-Colas L, Soloway I, Batchelder A, Litwin AH. Reducing barriers to hepatitis C treatment among drug users: an integrated hepatitis C peer education and support program. J Health Care Poor Underserved. 2014;25(2):652-62.
39. Stein MR, Soloway IJ, Jefferson KS, Roose RJ, Arnsten JH, Litwin AH. Concurrent group treatment for hepatitis C: implementation and outcomes in a methadone maintenance treatment program. J Subst Abuse Treat. 2012;43(4):424-32.
40. Braun V, Clarke V. Using thematic analysis in psychology. Qual Res Psychol. 2006;3(2):77-101.
41. Glaser BG, Strauss AL. The discovery of grounded theory: strategies for qualitative research. Chicago, IL: Aldine Publishing Company; 1967.
42. Ly KN, Xing J, Klevens RM, Jiles RB, Ward JW, Holmberg SD. The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007. Ann Intern Med. 2012;156(4):271-8.
43. Chen E, North C, Fatunde O, Bernstein I, Salari S, Day B, et al. Knowledge and attitudes about hepatitis C virus (HCV) infection and its treatment in HCV mono infected and HCV/HIV coinfected adults. J Viral Hepat. 2013;20(10):708-14.